MRD as Biomarker for Response to Donor Lymphocyte Infusion after Allogeneic Hematopoietic Cell Transplantation in Patients with AML.

Cancers (Basel) · 2023 · PMC10416875 · PMID 37568726

Europe PMC DOI

hedged sentence

0.0700

closest p · 1.4× alpha

0.0700

boldest claim

The sentences

showed a trendp = 0.07so close (0.05 < p ≤ 0.1)

First, we looked at CR/CRi status at FU90 and found a trend for an association of chromatin-modifier mutations with a higher CR/CRi rate ( p = 0.07), whereas mutations in tumor-suppressor genes showed a trend for a lower CR/CRi rate ( p = 0.07) ( Supplementary Table S4 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.